X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.310
+0.170 (4.11%)
At close: May 29, 2026, 4:00 PM EDT
4.400
+0.090 (2.09%)
After-hours: May 29, 2026, 5:22 PM EDT

X4 Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
40736412514012164
Market Cap Growth
2021.64%189.93%-10.69%16.23%87.57%-38.56%
Enterprise Value
250.05186.92100.1983.393520.54
Last Close Price
4.314.0022.0125.1629.7968.70
PS Ratio
45.1010.3649.05---
PB Ratio
2.411.955.662.751.631.00
P/TBV Ratio
1.850.916.662.920.850.92
EV/Sales Ratio
27.745.3239.18---
Debt / Equity Ratio
0.450.413.471.120.490.59
Net Debt / Equity Ratio
-0.93-0.94-1.08-1.09-1.13-0.65
Net Debt / EBITDA Ratio
1.622.050.100.520.950.50
Net Debt / FCF Ratio
1.662.050.180.581.080.59
Asset Turnover
0.030.160.02000
Inventory Turnover
0.361.580.57---
Quick Ratio
9.889.843.165.025.505.89
Current Ratio
10.1810.163.415.345.766.27
Return on Equity (ROE)
-56.22%-75.99%-102.26%-161.83%-135.70%-129.30%
Return on Assets (ROA)
-34.87%-39.79%-169.19%-71.06%-64.97%-70.92%
Return on Invested Capital (ROIC)
-708.43%-670.61%-2067.04%-849.42%-475.23%-302.73%
Return on Capital Employed (ROCE)
-38.24%-45.94%-207.09%-83.46%-74.94%-79.51%
Buyback Yield / Dilution
-968.53%-531.04%-13.08%-179.91%-146.71%-28.25%
Total Shareholder Return
-968.53%-531.04%-13.08%-179.91%-146.71%-28.25%
Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q